Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.

We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC-1) gene could be more genetically instable and consequently more responsive to a programmed cell death-1 (PD-1) blockade. We evaluated the and SNPs by pyrosequencing assay, on tumor specimens from two independent cohorts of patients who relapsed after one or more prior systemic treatments for advanced NSCLC and who received nivolumab (3 mg/kg intravenously every 2 weeks) as part of the Italian Expanded Access Program. We aimed to assess the outcome of enrolled subjects according to the SNPs , to evaluate the role of these polymorphisms as putative biomarkers associated with a response/clinical benefit to anti-PD-1 therapies. Of the 45 patients included in the final analysis, 21 (47%) and 16 (36%) were positive for the and polymorphic genotype (PG), respectively. In univariate analyses, overall survival (OS) and progression free survival (PFS) were shorter in patients with the PG, but neither difference achieved statistical significance ( = 0.131 and = 0.717, respectively). The presence of the PG was associated with a longer OS and PFS, although statistical significance was only reached for PFS ( = 0.112 and = 0.025, respectively). These results were confirmed by multivariate analyses. The response rate was only significantly higher in patients with the PG vs. wild type (62 vs. 7%, < 0.001). Results from this hypothesis generating pilot study, provided suggestive evidence that a subgroup of NSCLC patients could benefit differently from nivolumab according to the SNP . However, these data warrant further investigation.